Spots Global Cancer Trial Database for lip
Every month we try and update this database with for lip cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | NCT03529422 | Larynx Lip Oral Cancer Digestive Organ... | Durvalumab Intensity Modul... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer | NCT01185171 | Head and Neck C... | ZD 1839 500mg | 18 Years - | University of Chicago | |
| S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | NCT00100789 | Head and Neck C... | gemcitabine paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer | NCT03109873 | Larynx Lip Oral Cavity Pharynx | External Beam R... Metformin Hydro... Placebo | 18 Years - 90 Years | Thomas Jefferson University | |
| Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | NCT03529422 | Larynx Lip Oral Cancer Digestive Organ... | Durvalumab Intensity Modul... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck Cancer | NCT01187472 | Head and Neck C... | 59 Years - | University of Chicago | ||
| Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | NCT03076281 | Larynx LIP Oral Cavity Pharynx | Metformin Hydro... Doxycycline Metformin +Doxy... | 18 Years - | Thomas Jefferson University | |
| Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck Cancer | NCT01187472 | Head and Neck C... | 59 Years - | University of Chicago | ||
| Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | NCT03076281 | Larynx LIP Oral Cavity Pharynx | Metformin Hydro... Doxycycline Metformin +Doxy... | 18 Years - | Thomas Jefferson University | |
| A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma | NCT01185158 | Head and Neck C... | ZD1839 (IRESSA) | 18 Years - | University of Chicago | |
| T1 Squamous Cell Carcinomas of the Lip | NCT05610293 | Lip Lip Cancer Lip SCC Squamous Cell C... Squamous Cell C... Surgery Surgical Margin Recurrence Metastasis Tumor Free Marg... | 18 Years - | Maastricht University Medical Center | ||
| Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck | NCT03854032 | Lip Oral Cavity Squ... Pharynx Larynx Squamous Cell C... | Nivolumab IDO1 Inhibitor ... Therapeutic Con... Questionnaire A... | 18 Years - | Thomas Jefferson University | |
| S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | NCT00100789 | Head and Neck C... | gemcitabine paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma | NCT01185158 | Head and Neck C... | ZD1839 (IRESSA) | 18 Years - | University of Chicago | |
| Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | NCT03529422 | Larynx Lip Oral Cancer Digestive Organ... | Durvalumab Intensity Modul... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| T1 Squamous Cell Carcinomas of the Lip | NCT05610293 | Lip Lip Cancer Lip SCC Squamous Cell C... Squamous Cell C... Surgery Surgical Margin Recurrence Metastasis Tumor Free Marg... | 18 Years - | Maastricht University Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
